MedTrace Logo

A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects

NCT07185113 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-05-15

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the pharmacokinetics (how the body interacts with administered substances for the entire duration of exposure) of Gen-1124 in an oral formulation (taken by mouth) in healthy volunteers. It will also learn about the safety of Gen-1124. The main questions it aims to answer are:

\- How does Gen-1124 interact with a human body?

Researchers will look at how Gen-1124 interacts with the body and what side effects it may cause.

Participants will:

* Take Gen-1124 for a single dose
* Remain in clinic for 2 days for checkups and tests
* Recieve a phone call for a checkup 3 and 7 days after the single dose

Conditions

  • Healthy Adult Male

Interventions

DRUG

GEn-1124

GEn-1124 will be administered to one single dose group of subjects dosed under fed (standardized meal) conditions. GEn-1124 will be administered as an oral capsule formulation containing GEn-1124.

Sponsors & Collaborators

  • InClin, Inc.

    collaborator UNKNOWN

  • GEn1E Lifesciences

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-29
Primary Completion
2025-11-04
Completion
2025-11-04

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185113 on ClinicalTrials.gov